메뉴 건너뛰기




Volumn 64, Issue 3, 2004, Pages 117-122

Gefitinib - Experience with a biologically targeted therapy of non-small-cell lung carcinoma;Gefitinib - Zkušenosti s biologicky cílenou terapií nemalobuněčného karcinomu plic

Author keywords

Biologically targeted therapy; Gefitinib; Inhibitors of EGF receptor; Inhibitors of tyrosinkinase

Indexed keywords

CYTOSTATIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

EID: 4644229846     PISSN: 1213810X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)

References (14)
  • 1
    • 1242283946 scopus 로고    scopus 로고
    • Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    • Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43:317-322.
    • (2004) Lung Cancer , vol.43 , pp. 317-322
    • Argiris, A.1    Mittal, N.2
  • 3
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II traal of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    • Fukuoka M, Yano S, Giaccone G, et al. Multi-Institutional Randomized Phase II Traal of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Jour Clin Oncol 2003; 21:2237-46.
    • (2003) Jour Clin Oncol , vol.21 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 4
    • 1542503756 scopus 로고    scopus 로고
    • Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
    • Giaccone G, Herbst RS, Manegold Ch, et al. Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact? Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial - INTACT 1 Jour Clin Oncol 2004;22:759-761.
    • (2004) Jour Clin Oncol , vol.22 , pp. 759-761
    • Giaccone, G.1    Herbst, R.S.2    Manegold, Ch.3
  • 5
    • 1542503756 scopus 로고    scopus 로고
    • Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
    • Herbst RS, et al. Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact? Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial - INTACT 2 Jour Clin Oncol 2004;22:759-761.
    • (2004) Jour Clin Oncol , vol.22 , pp. 759-761
    • Herbst, R.S.1
  • 6
    • 0142119289 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis
    • Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Jour Clin Oncol 2003;21:3798-3807.
    • (2003) Jour Clin Oncol , vol.21 , pp. 3798-3807
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn Jr., P.A.3
  • 7
    • 0037811751 scopus 로고    scopus 로고
    • Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?
    • Editorials
    • Johnson DH, Arteaga CL. Gefitinib in Recurrent Non-Small-Cell Lung Cancer: An IDEAL Trial? Jour Clin Oncol 2003;21Editorials:2227-29.
    • (2003) Jour Clin Oncol , vol.21 , pp. 2227-2229
    • Johnson, D.H.1    Arteaga, C.L.2
  • 8
    • 3242669300 scopus 로고    scopus 로고
    • The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumors
    • poster A-100
    • McKillop D, Stephens TC, Partridge EA, et al. The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumors. Clini Cancer Res A ACR-NCI-EORTC 2003;9(16 Pt 2 Suppl S):6093, poster A-100.
    • (2003) Clini Cancer Res A ACR-NCI-EORTC , vol.9 , Issue.16 PART 2 AND SUPPL. S , pp. 6093
    • McKillop, D.1    Stephens, T.C.2    Partridge, E.A.3
  • 9
    • 1842509828 scopus 로고    scopus 로고
    • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    • Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer. Jour Clin Oncol 2004; 22:1103-9.
    • (2004) Jour Clin Oncol , vol.22 , pp. 1103-1109
    • Miller, V.A.1    Kris, M.G.2    Shah, N.3
  • 10
    • 84862425464 scopus 로고    scopus 로고
    • Pre-operative induction gefitinib (Iressa, ZD 1839) treatment in a patient with relapsing bronchioloalveolar carcinoma
    • Madrid, Spain, 28. 6 - abstracts
    • Pešek M, Eliasová B. Pre-operative induction gefitinib (Iressa, ZD 1839) treatment in a patient with relapsing bronchioloalveolar carcinoma. Iressa Clinical Experience Meeting, Madrid, Spain, 28. 6. 2003 - abstracts.
    • (2003) Iressa Clinical Experience Meeting
    • Pešek, M.1    Eliasová, B.2
  • 11
    • 1342268525 scopus 로고    scopus 로고
    • American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
    • Pfister DG, Jonhson DH, Azzoli ChG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 Jour Clin Oncol 2004;22:330-353.
    • (2004) Jour Clin Oncol , vol.22 , pp. 330-353
    • Pfister, D.G.1    Jonhson, D.H.2    Azzoli, Ch.G.3
  • 12
    • 0033762484 scopus 로고    scopus 로고
    • The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents
    • Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000; 60:1-14.
    • (2000) Drugs , vol.60 , pp. 1-14
    • Rowinsky, E.K.1
  • 13
    • 85047691722 scopus 로고    scopus 로고
    • Gefitinib (Iressa): A novel treatment for non-small cell lung cancer
    • Vansteenkiste JF. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Exp Rev Anti-cancer Ther 2004;4:5-17.
    • (2004) Exp Rev Anti-cancer Ther , vol.4 , pp. 5-17
    • Vansteenkiste, J.F.1
  • 14
    • 4644310711 scopus 로고    scopus 로고
    • Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib ('Iressa', ZD1839) in an expanded access program (EAP): Preliminary results
    • Wolf M, Farina Sisofo D, et al. Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib ('Iressa', ZD1839) in an expanded access program (EAP): Preliminary results. Eur J Cancer Supplements 2003;1:248.
    • (2003) Eur J Cancer Supplements , vol.1 , pp. 248
    • Wolf, M.1    Farina Sisofo, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.